TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2588205

Group type: COMPARATOR
Intervention: Metered dose inhaler alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer (slow inhaled flow rate, about 25 l/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer (fast inhaled flow rate, about 100 l/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer (slow inhaled flow rate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler plus spacer
Number of subjects: 10
Study: 796943

Group type: EXPERIMENTAL
Intervention: Ketoprofen (150 mg daily in three divided doses of 50 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31428908

Group type: EXPERIMENTAL
Intervention: Lapatinib, trastuzumab, or the combination with chemotherapy
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Trastuzumab-containing regimens
Number of subjects: 271

Group type: COMPARATOR
Intervention: Dual HER2-targeted therapy versus trastuzumab
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: HER2E tumors
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Higher ESR1 gene expression
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Subtype
Number of subjects: 271
Study: 28362143

Group type: EXPERIMENTAL
Intervention: Foot centered position with hands free
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toe fixed position with hands on hips
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toe-heel changing position with hands on hips
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Any combination of foot alignments and/or hand constraints
Number of subjects: 25
Study: 26298020

Group type: EXPERIMENTAL
Intervention: Typical postoperative ankle brace with unrestricted ROM
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Typical postoperative ankle brace fixed at 15° plantar flexion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Typical postoperative ankle brace restricted with 15°/50° dorsal/plantar flexion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Brace for ligament instabilities
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Elastic ankle bandage
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (without a brace)
Number of subjects: 70
Study: 23123382

Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 200

Group type: COMPARATOR
Intervention: Early cord clamping (control)
Number of subjects: 200
Study: 21752826

Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 19527449

Group type: EXPERIMENTAL
Intervention: Aironet educational program (received at baseline and 2 months later)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Aironet educational program
Number of subjects: 123
Study: 16643703

Group type: EXPERIMENTAL
Intervention: Efficacy-before-threat leaflet
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Threat-before-efficacy leaflet
Number of subjects: 178

Group type: COMPARATOR
Intervention: No leaflet (control)
Number of subjects: 178
Study: 14985220

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily for 2 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (multivitamin alone)
Number of subjects: 56
Study: 11341459

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment after trial
Number of subjects: 18
Study: 9145841

Group type: EXPERIMENTAL
Intervention: Ritonavir 200 mg every 12 h for 2 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg every 12 h for 2 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg every 12 h for 2 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ritonavir 500 mg every 12 h for 2 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 29114896

Group type: EXPERIMENTAL
Intervention: Shared decision-making tool
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no shared decision-making tool)
Number of subjects: 50
Study: 27401788

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d for 12 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 71
Study: 24738701

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23733798

Group type: EXPERIMENTAL
Intervention: 20 mg of zinc orally every day for 2 weeks
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo suspension orally every day for 2 weeks
Number of subjects: 272
Study: 19266828

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 microg kg(‐1) as preinduction over 15 min and 0.2‐1 microg kg(‐1) hr(‐1) by continuous i.v. infusion during operation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Remifentanil 1 microg kg(‐1) as induction i.v. over 15 min and 0.05‐1 microg kg(‐1) min(‐1) as maintenance
Number of subjects: 50
Study: 17290160

Group type: EXPERIMENTAL
Intervention: Isoflavones (60 mg daily for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15326072

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 960

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 960
Study: 11802818

Group type: EXPERIMENTAL
Intervention: Three different road safety interventions: 1) three-dimensional model of the traffic environment; 2) road safety board game; 3) illustrated posters and flip-chart materials.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Training from the road safety interventions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (children who did not receive the interventions)
Number of subjects: 120
Study: 9723661

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8036464

Group type: EXPERIMENTAL
Intervention: Hemoccult II fecal occult blood testing (performed on 3 days and repeated after 16 to 24 months)
Number of subjects: 68308

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68308
Study: 2713513

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, adjusted loco-regional treatment (surgery and/or radiotherapy) and adjuvant chemotherapy with or without immunostimulation
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Hormonotherapy for tumoral reduction
Number of subjects: 279
Study: 1094562

Group type: EXPERIMENTAL
Intervention: Clofibrate (Ciba‐SU13437)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combination of clofibrate and cholestyramine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 19
Study: 30883047

Group type: EXPERIMENTAL
Intervention: PB2452
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27566993

Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Reduction intervention
Number of subjects: 560

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 560
Study: 24227448

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 23
Study: 23782510

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (12 weeks of physical exercise and psycho-educational intervention with five consultations)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation
Number of subjects: 210
Study: 21315206

Group type: EXPERIMENTAL
Intervention: Radial access for coronary angiography/intervention
Number of subjects: 7021

Group type: COMPARATOR
Intervention: Femoral access for coronary angiography/intervention
Number of subjects: 7021
Study: 19059545

Group type: EXPERIMENTAL
Intervention: Preconception counseling (PCC)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 633
Study: 17852628

Group type: EXPERIMENTAL
Intervention: 1072 nm light treatment for a period of between 6 and 8 weeks
Number of subjects: 0
Study: 15082593

Group type: EXPERIMENTAL
Intervention: Polyurethane covered stent (n = 57)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Original diamond stent (n = 55)
Number of subjects: 112
Study: 11679859

Group type: EXPERIMENTAL
Intervention: 10 mg prochlorperazine administered intravenously by means of 2‐minute push (bolus group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: 10 mg prochlorperazine diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15‐minute period (infusion group)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Bolus group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Infusion group
Number of subjects: 99
Study: 9175991

Group type: EXPERIMENTAL
Intervention: Low-sodium diet (mean urinary Na excretion 61 mmol/24 h)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (mean urinary Na excretion 142 mmol/24 h)
Number of subjects: 94
Study: 8200248

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (Lupron Depot 3.75 mg for one month, then daily subcutaneous dose increased from 0.5 mg to 1.0-1.5 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (maximum therapeutic dosage)
Number of subjects: 28
Study: 2828072

Group type: EXPERIMENTAL
Intervention: High-dose etoposide (350 mg/m2/day for 5 days) and cisplatin (40 mg/m2/day for 5 days)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose etoposide (350 mg/m2/day for 5 days)
Number of subjects: 12
Study: 30824430

Group type: EXPERIMENTAL
Intervention: Creative Writing Workshops (CWW) - 4 sessions of 2 hours each over 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard of Care (SOC) - no participation in CWW
Number of subjects: 16
Study: 31005942

Group type: EXPERIMENTAL
Intervention: Transcutaneous bilirubin (TcB) screening
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Primary care-based phototherapy
Number of subjects: 5500
Study: 28547955

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 100
Study: 25880483

Group type: EXPERIMENTAL
Intervention: Breastfed (yes)
Number of subjects: 4335

Group type: COMPARATOR
Intervention: Breastfed (no)
Number of subjects: 4335
Study: 23635621

Group type: EXPERIMENTAL
Intervention: Faculty-directed sessions in a simulation laboratory
Number of subjects: 116

Group type: COMPARATOR
Intervention: Traditional teaching (no simulation)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Simulation group
Number of subjects: 116
Study: 21898419

Group type: EXPERIMENTAL
Intervention: Medialization laryngoplasty (ML)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laryngeal reinnervation (LR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 19187377

Group type: EXPERIMENTAL
Intervention: Continuous sutures
Number of subjects: 445

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 445
Study: 16960414

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg kg(‐1) IV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sevoflurane (7% in O(2) at 6L min(‐1) for 2 minutes)
Number of subjects: 44
Study: 15082207

Group type: EXPERIMENTAL
Intervention: Vardenafil 10mg (flexible dosing allowed: 5mg, 10mg, or 20mg)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 323
Study: 11174341

Group type: EXPERIMENTAL
Intervention: Milrinone bolus followed by continuous infusion (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo bolus followed by continuous milrinone infusion (n = 10)
Number of subjects: 19
Study: 9508162

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) alone
Number of subjects: 1740

Group type: COMPARATOR
Intervention: Combined modality treatment (CT + RT)
Number of subjects: 1740

Group type: EXPERIMENTAL
Intervention: Additional RT after CT
Number of subjects: 1740

Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 1740

Group type: COMPARATOR
Intervention: No RT
Number of subjects: 1740
Study: 8165955

Group type: EXPERIMENTAL
Intervention: New Marburg rehabilitation concept (group A) - additional twice a week exercise in a fitness center under medical supervision
Number of subjects: 40

Group type: COMPARATOR
Intervention: Out-patient physiotherapy only (group B)
Number of subjects: 40
Study: 3073463

Group type: EXPERIMENTAL
Intervention: Urokinase (small repeated doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Urokinase (large single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Urokinase and Heparin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 30
Study: 30879076

Group type: EXPERIMENTAL
Intervention: Clinically negligible RKF
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Higher dialysis dose (spKt/Vurea 1.7)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Preserved RKF at 1-year follow-up
Number of subjects: 1280
Study: 31335651

Group type: EXPERIMENTAL
Intervention: Pregabalin (titrated to maximum dose 600 mg per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pregabalin (in post hoc analysis for patients with CIPN caused by oxaliplatin)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (in post hoc analysis for patients with CIPN caused by oxaliplatin)
Number of subjects: 26
Study: 29164923

Group type: EXPERIMENTAL
Intervention: Traditional tongue depressors
Number of subjects: 92

Group type: COMPARATOR
Intervention: Flavored tongue depressors
Number of subjects: 92
Study: 26625980

Group type: EXPERIMENTAL
Intervention: mHealth assisted healthy lifestyle intervention package including motivational counseling, low GI nutritional advice, daily physical activity prescription, and smartphone app support
Number of subjects: 253

Group type: COMPARATOR
Intervention: Standard obstetric care
Number of subjects: 253
Study: 24448262

Group type: EXPERIMENTAL
Intervention: Topical tetracycline for children younger than 6 months and oral azithromycin for those 6 months and older (annual MDA)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: One additional MDA
Number of subjects: 13
Study: 22241792

Group type: EXPERIMENTAL
Intervention: Single-agent lenalidomide with pneumococcal 7-valent conjugate vaccine (PCV) in Cohort B (both vaccinations while on lenalidomide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent lenalidomide with pneumococcal 7-valent conjugate vaccine (PCV) in Cohort A (first vaccination prior to lenalidomide, second while on lenalidomide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical myeloma response
Number of subjects: 0
Study: 20630093

Group type: EXPERIMENTAL
Intervention: Custom made neck jig device
Number of subjects: 5
Study: 17669103

Group type: EXPERIMENTAL
Intervention: S. boulardii
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 15521079

Group type: EXPERIMENTAL
Intervention: 3000 ml normal saline intravenously for 24 h before drainage
Number of subjects: 49

Group type: COMPARATOR
Intervention: No saline infusion (control group)
Number of subjects: 49
Study: 11981147

Group type: EXPERIMENTAL
Intervention: Clevidipine (doses greater than or equal to 1.37 microg.kg-1.min-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 0
Study: 9442774

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 276

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 276
Study: 7884257

Group type: EXPERIMENTAL
Intervention: Allopurinol (100-300 mg/day for seven days before operation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study: 2224784

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimen A1 (cyclophosphamide 1200 mg/m2, vincristine 1.5 mg/m2, pyrarubicin 40 mg/m2, cisplatin 90 mg/m2) followed by bone marrow transplantation (BMT)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) after complete remission
Number of subjects: 109

Group type: COMPARATOR
Intervention: Alternating treatment by regimen B (cyclophosphamide and ACNU) and intensified regimen A1
Number of subjects: 109

Group type: COMPARATOR
Intervention: Alternating administration of regimen C (cyclophosphamide and DTIC) and intensified A1
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Intensive induction chemotherapy
Number of subjects: 109
Study: 534065

Group type: EXPERIMENTAL
Intervention: 30% urea (intravenous)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 20% mannitol (intravenous)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Furosemide (intravenous)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 30% urea (oral)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 10% glycerol (oral)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Continuous infusion of thiopental (in conjunction with hyperosmotic agents)
Number of subjects: 90
Study: 31599194

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clustered allocation
Number of subjects: 0

Group type: COMPARATOR
Intervention: External patients as controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian and frequentist approaches
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical dataset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental arm recruitment plan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finalised analysis plan
Number of subjects: 0
Study: 29992831

Group type: EXPERIMENTAL
Intervention: MPFF 1000 mg once daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: MPFF 500 mg twice daily
Number of subjects: 87
Study: 29020293

Group type: EXPERIMENTAL
Intervention: Dual therapy with darunavir/ritonavir and lamivudine
Number of subjects: 249

Group type: COMPARATOR
Intervention: Triple therapy with darunavir/ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine
Number of subjects: 249
Study: 26169691

Group type: EXPERIMENTAL
Intervention: 1064-nm Q-switched Nd:YAG laser treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: 532-nm Q-switched Nd:YAG laser treatment
Number of subjects: 32
Study: 23427000

Group type: EXPERIMENTAL
Intervention: GS-9667 (30-1,800 mg single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GS-9667 (600-2,400 mg QD, 1,200 mg BID, or 600 mg QID for 14 days)
Number of subjects: 0
Study: 21111684

Group type: EXPERIMENTAL
Intervention: Escalating Dose
Number of subjects: 135

Group type: COMPARATOR
Intervention: Stable Dose
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study: 19744761

Group type: EXPERIMENTAL
Intervention: Definite Multibond+Definite
Number of subjects: 24

Group type: COMPARATOR
Intervention: Syntac+Variolink Ultra
Number of subjects: 24
Study: 16925467

Group type: EXPERIMENTAL
Intervention: High sodium diet (200 mEq)
Number of subjects: 28
Study: 15119920

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 157

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 157
Study: 11755586

Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Planned vaginal delivery
Number of subjects: 0
Study: 9136940

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2A (Roferon‐A) as a co‐induction agent with intensive combination chemotherapy (PCAB: prednisone 60 mg/m2 days 1‐5, cyclophosphamide 600 mg/m2 day 1, BCNU 30 mg/m2 day 1, doxorubicin 30 mg/m2 day 1, repeated every 28 d for a total of 12 cycles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2A (Roferon‐A) for patients who achieved plateau phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive combination chemotherapy (PCAB) without interferon
Number of subjects: 0
Study: 8201815

Group type: EXPERIMENTAL
Intervention: Video projection of humorous movies four times daily for 3 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: Video projections of other assorted movies at the same rate
Number of subjects: 2
Study: 3720035

Group type: EXPERIMENTAL
Intervention: Intensive dialysis (maintaining predialysis blood urea nitrogen below 60 mg/dl and serum creatinine below 5 mg/dl)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-intensive dialysis (maintaining predialysis blood urea nitrogen below 100 mg/dl and serum creatinine below 9 mg/dl)
Number of subjects: 34
Study: 28551715

Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methylphenidate (60 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modafinil (600 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26860794

Group type: EXPERIMENTAL
Intervention: Seated Tai Chi exercise (40 min, three times a week for 26 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Seated Tai Chi exercise
Number of subjects: 60
Study: 25004111

Group type: EXPERIMENTAL
Intervention: Venom Immunotherapy (VIT) for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-allergic healthy controls
Number of subjects: 0
Study: 22730857

Group type: EXPERIMENTAL
Intervention: PC-coated CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (uncoated CPB)
Number of subjects: 40
Study: 15911424

Group type: EXPERIMENTAL
Intervention: d4T/3TC/IDV
Number of subjects: 27

Group type: COMPARATOR
Intervention: AZT/3TC/IDV
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups (d4T/3TC/IDV and AZT/3TC/IDV)
Number of subjects: 27
Study: 12394199

Group type: COMPARATOR
Intervention: No salt (control group)
Number of subjects: 38
Study: 9987043

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 0
Study: 7762912

Group type: EXPERIMENTAL
Intervention: Heparin at a bolus dose of 2000 U at the initiation of dialysis followed by 1000 U/h during 4-hour hemodialysis sessions
Number of subjects: 13